Literature DB >> 29356965

NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.

Charlotte Flüh1, Guranda Chitadze2, Vivian Adamski3, Kirsten Hattermann4, Michael Synowitz3, Dieter Kabelitz2, Janka Held-Feindt3.   

Abstract

Glioblastoma multiforme (GBM) is a highly malignant brain tumor. Tumor stem cells have a major influence on tumor malignancy, and immunological escape mechanisms, involving the Natural Killer Group 2, member D (NKG2D) receptor-ligand-system, are key elements in tumor immuno-surveillance. We analyzed the expression profile and localization of NKG2D ligands (NKG2DL) and embryonic and neural stem cell markers in solid human GBM and stem-like cells isolated from glioma cell lines by qRT-PCR and immunohistochemistry, including quantitative analysis. We also evaluated the effect of Temozolomide (TMZ), the standard chemotherapeutic agent used in GBM therapy, on NKG2DL expression. NKG2DL-positive cells were mostly found scattered and isolated, were detectable in glial fibrillary acidic protein (GFAP)-positive tumor regions and partly in the penumbra of tumor vessels. NKG2DL were found in a distinct tumor stem-like cell subpopulation and were broadly costained with each other. Quantitative analysis revealed, that dependent on the individual NKG2DL investigated, cell portions costained with different stem cell markers varied between small (Musashi-1) and high (KLf-4) amounts. However, a costaining of NKG2DL with CD3γ, typically found in T cells, was also observable, whereas CD11b as a marker for tumor micoglia cells was only rarely costained with NKG2DL. Stem-like cells derived from the glioma cell lines T98G and U251MG showed a distinct expression pattern of NKG2DL and stem cell markers, which seemed to be balanced in a cell line-specific way. With differentiation, T98G displayed less NKG2DL, whereas in U251MG, only expression of most stem cell markers decreased. In addition, stimulation with TMZ led to a significant upregulation of NKG2DL in stem-like cells of both lines. As stem-like glioma cells tend to show a higher expression of NKG2DL than more differentiated tumor cells and TMZ treatment supports upregulation of NKG2DL, the NKG2D system might play an important role in tumor stem cell survival and in GBM therapy.

Entities:  

Keywords:  Glioblastoma; MICA; MICB; NKG2DL; Stem cells; Temozolomide

Mesh:

Substances:

Year:  2018        PMID: 29356965     DOI: 10.1007/s00418-018-1633-5

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  46 in total

Review 1.  Cancer stem cells: A contentious hypothesis now moving forward.

Authors:  Michael L O'Connor; Dongxi Xiang; Sarah Shigdar; Joanna Macdonald; Yong Li; Tao Wang; Chunwen Pu; Zhidong Wang; Liang Qiao; Wei Duan
Journal:  Cancer Lett       Date:  2013-12-11       Impact factor: 8.679

2.  CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs).

Authors:  Janka Held-Feindt; Kirsten Hattermann; Susanne Sebens Müerköster; Hanna Wedderkopp; Friederike Knerlich-Lukoschus; Hendrik Ungefroren; H Maximilian Mehdorn; Rolf Mentlein
Journal:  Exp Cell Res       Date:  2010-02-23       Impact factor: 3.905

3.  Immunological characterization of glioblastoma cells for immunotherapy.

Authors:  Tae-Young Jung; Yoo-Duk Choi; Young-Hee Kim; Je-Jung Lee; Hyung-Seok Kim; Ju-Sun Kim; Sang-Ki Kim; Shin Jung; Duck Cho
Journal:  Anticancer Res       Date:  2013-06       Impact factor: 2.480

4.  Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro.

Authors:  Tatyana N Ignatova; Valery G Kukekov; Eric D Laywell; Oleg N Suslov; Frank D Vrionis; Dennis A Steindler
Journal:  Glia       Date:  2002-09       Impact factor: 7.452

5.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

6.  Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity.

Authors:  Roberta Castriconi; Alessandra Dondero; Francesca Negri; Francesca Bellora; Paolo Nozza; Barbara Carnemolla; Alessandro Raso; Lorenzo Moretta; Alessandro Moretta; Cristina Bottino
Journal:  Eur J Immunol       Date:  2007-11       Impact factor: 5.532

7.  MICA/NKG2D-mediated immunogene therapy of experimental gliomas.

Authors:  Manuel A Friese; Michael Platten; Stefan Z Lutz; Ulrike Naumann; Steffen Aulwurm; Felix Bischof; Hans-Jörg Bühring; Johannes Dichgans; Hans-Georg Rammensee; Alexander Steinle; Michael Weller
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

8.  MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape.

Authors:  Paula Codo; Michael Weller; Gunter Meister; Emese Szabo; Alexander Steinle; Marietta Wolter; Guido Reifenberger; Patrick Roth
Journal:  Oncotarget       Date:  2014-09-15

9.  Glioma Stemlike Cells Enhance the Killing of Glioma Differentiated Cells by Cytotoxic Lymphocytes.

Authors:  Esen Yonca Bassoy; Valentina Chiusolo; Guillaume Jacquemin; Cristina Riccadonna; Paul R Walker; Denis Martinvalet
Journal:  PLoS One       Date:  2016-04-13       Impact factor: 3.240

10.  Cancer Stem Cells in Glioblastoma Multiforme.

Authors:  Amy Bradshaw; Agadha Wickremesekera; Helen D Brasch; Alice M Chibnall; Paul F Davis; Swee T Tan; Tinte Itinteang
Journal:  Front Surg       Date:  2016-08-26
View more
  11 in total

1.  Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells.

Authors:  Jiao Wang; Sandra Toregrosa-Allen; Bennett D Elzey; Sagar Utturkar; Nadia Atallah Lanman; Victor Bernal-Crespo; Matthew M Behymer; Gregory T Knipp; Yeonhee Yun; Michael C Veronesi; Anthony L Sinn; Karen E Pollok; Randy R Brutkiewicz; Kathryn S Nevel; Sandro Matosevic
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-09       Impact factor: 12.779

Review 2.  Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.

Authors:  Daniel Kreatsoulas; Chelsea Bolyard; Bill X Wu; Hakan Cam; Pierre Giglio; Zihai Li
Journal:  J Hematol Oncol       Date:  2022-06-11       Impact factor: 23.168

Review 3.  Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression.

Authors:  Amber B Jones; Abbey Rocco; Lawrence S Lamb; Gregory K Friedman; Anita B Hjelmeland
Journal:  Cancers (Basel)       Date:  2022-05-09       Impact factor: 6.575

4.  T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.

Authors:  Dong Yang; Bin Sun; Hongjiu Dai; Wenxuan Li; Lan Shi; Peixian Zhang; Shirong Li; Xudong Zhao
Journal:  J Immunother Cancer       Date:  2019-07-09       Impact factor: 13.751

Review 5.  Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.

Authors:  Yutao Li; Amit Sharma; Jarek Maciaczyk; Ingo G H Schmidt-Wolf
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

Review 6.  Targeting Tumor-Associated Antigen: A Promising CAR-T Therapeutic Strategy for Glioblastoma Treatment.

Authors:  Guidong Zhu; Qing Zhang; Junwen Zhang; Fusheng Liu
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810

Review 7.  Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.

Authors:  Timm Hoeres; Manfred Smetak; Dominik Pretscher; Martin Wilhelm
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

8.  Rae1 drives NKG2D binding-dependent tumor development in mice by activating mTOR and STAT3 pathways in tumor cells.

Authors:  Peiyan Zhao; Lei Yang; Xin Li; Wenting Lu; Fangjie Lu; Shengnan Wang; Ying Wang; Li Hua; Cuiyun Cui; Boqi Dong; Yongli Yu; Liying Wang
Journal:  Cancer Sci       Date:  2020-05-16       Impact factor: 6.716

9.  Dormancy and NKG2D system in brain metastases: Analysis of immunogenicity.

Authors:  Charlotte Flüh; Victor Mafael; Vivian Adamski; Michael Synowitz; Janka Held-Feindt
Journal:  Int J Mol Med       Date:  2019-12-30       Impact factor: 4.101

10.  Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche.

Authors:  Deniz Caylioglu; Rieke Johanna Meyer; Dana Hellmold; Carolin Kubelt; Michael Synowitz; Janka Held-Feindt
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.